Payment overview · 2025
General Payments
$646.35
27 reported records · 9 companies
Healthcare provider profile · identity verified
Eun Joo Oh, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · ORO VALLEY, AZ · NPI 1558391672
Verified facts
What the public records show
CMS Open Payments records show Eun Joo Oh, MD received $646.35 in general payments during 2025 across 27 reported records.
AstraZeneca Pharmaceuticals LP accounted for 38.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Paxlovid, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $249.55 | 38.6% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $77.86 | 12.1% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $70.74 | 10.9% | 4 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $67.20 | 10.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $49.43 | 7.7% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $40.78 | 6.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.29 | 6.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.37 | 5.3% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.13 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $646.35 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $124.55 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $70.74 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $56.39 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $49.43 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $48.99 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $41.31 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $40.78 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $40.29 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $36.55 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $36.55 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $36.55 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $34.37 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $30.26 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 45 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
100 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
45 | 41 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 337 | 93 |
| Lisinopril | Lisinopril | 163 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 148 | 42 |
| Ozempic | Semaglutide | 127 | 24 |
| Amlodipine Besylate | Amlodipine Besylate | 119 | 29 |
| Synthroid | Levothyroxine Sodium | 100 | 25 |
| Trazodone Hcl | Trazodone Hcl | 98 | 27 |
| Atorvastatin Calcium | Atorvastatin Calcium | 94 | 24 |
| Valsartan | Valsartan | 92 | 22 |
| Omeprazole | Omeprazole | 88 | 25 |
| Metformin Hcl Er | Metformin Hcl | 81 | 24 |
| Ezetimibe | Ezetimibe | 73 | 21 |
| Repatha Sureclick | Evolocumab | 68 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 66 | 29 |
| Montelukast Sodium | Montelukast Sodium | 66 | 16 |
| Rybelsus | Semaglutide | 66 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 17 |
| Gabapentin | Gabapentin | 61 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 13 |
| Tramadol Hcl | Tramadol Hcl | 54 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 45 | 41 |
| Ipratropium Bromide | Ipratropium Bromide | 43 | 22 |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 42 | 11 |
| Irbesartan | Irbesartan | 40 | 12 |
| Pregabalin | Pregabalin | 37 | 13 |
| Celecoxib | Celecoxib | 36 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 35 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Carvedilol | Carvedilol | 31 | suppressed |
| Eliquis | Apixaban | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Losartan Potassium | Losartan Potassium | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | suppressed |
| Metformin Hcl | Metformin Hcl | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Levoxyl | Levothyroxine Sodium | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 25 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 25 | 11 |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Cephalexin | Cephalexin | 22 | 12 |
| Creon | Lipase/Protease/Amylase | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Simvastatin | Simvastatin | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 14 |
| Alprazolam | Alprazolam | 19 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 12 |
| Estradiol | Estradiol | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 12 |
| Unithroid | Levothyroxine Sodium | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $646.35 · 27 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, COMIRNATY, EVENITY, FARXIGA, GVOKE HYPOPEN, KISUNLA, LEQVIO, PAXLOVID, PREVNAR 20, PROLIA, TEZSPIRE, TRINTELLIX, Tymlos, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error